Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px
All >

Deals > Switzerland

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Switzerland or involving Swiss organisations.

Total search results: 1089 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019 2019-01-10
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
Novartis–Qiagen: molecular companion diagnostics, 201812– collab devlepm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
JnJ–Argen-X: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
CRISPR Therapeutics–Barclays: investor conference, 201811 supply service CRISPR Tx presents at Barclays Gene Editing & Gene Therapy Summit 2018-11-29
CRISPR Therapeutics–Piper Jaffray: investor conference, 201811 supply service CRISPR Therapeutics at Piper Jaffray Healthcare Conference 2018 2018-11-28
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research 2018-11-15
Argen-X–Credit Suisse: investor conference, 201811 supply service Argenx presents at Credit Suisse Annual Healthcare Conference 2018 2018-11-14
Roivant–SEVERAL: investment, 201811 financing round $200m led by new investors NovaQuest Capital Management + RTW Investments 2018-11-13
Aimmune Therapeutics–Nestlé: investment, 201811 equity investment $98m w 3.24m shares at $30.27/share by Nestlé Health Science brings stake to 19% 2018-11-12
Amal Therapeutics–SEVERAL: investment, 201811 financing round Series B 2nd + final closing €21.2m co-led by BIVF + BioMedPartners + Helsinn 2018-11-12
CRISPR Therapeutics–MaxCyte: gene transfer technology, 201811– license commercial to use Flow Electroporation techn for CRISPR-based I-O therapies 2018-11-09
HBM–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D round 2018-11-01
Novartis–Philips: digital health, 201810– collab developm of SMART Suite by Alcon for cataract surgery on HealthSuite digital platform 2018-10-23
Endocyte–Novartis: investment, 201810– acquisition $2.1b in cash of Endocyte by Novartis ANNOUNCED 2018-10-18
JSR Corp–Berkeley Lights: cell line development, 201810– collab integrating SUREtechnology of Selexis with Beacon platform of BLI 2018-10-18
Genedata–AstraZeneca: bioinformatics, 2018 collab existent development of Genedata Imagence s/w for HCS image analysis 2018-10-16
CRISPR Therapeutics–Chardan: investor conference, 201810 supply service CRISPR presents at Chardan Genetic Medicines Conference in New York 2018-10-09
Sphingotec–HBM: investment, 201810 financing round totalling €20m incl co-lead investor HBM 2018-10-08
Sartorius–Genedata: bioinformatics, 201810 collab product integration of Genedata Bioprocess s/w with ambr mini bioreactos 2018-10-02
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics 2018-09-28
Bayer–Genedata: bioinformatics, 201809– license to Genedata Selector s/w for Bayer CropScience division for develop new fungicides 2018-09-27
Aktiia–Redalpine: investment, 201809 seed financing round totalling CHF4m led by TransLink Capital + Redalpine 2018-09-25
Aktiia–SEVERAL: investment, 201809 seed financing round CHF4m led by TransLink Capital + Redalpine 2018-09-25
Aktiia–TransLink Capital: investment, 201809 seed financing round totalling CHF4m led by TransLink Capital + Redalpine 2018-09-25
Tolremo Therapeutics–SEVERAL: investment, 201809 financing round Series A CHF9m led by BioMedPartners 2018-09-24
CRISPR Therapeutics–SEVERAL: investment, 201809 public offering $200m net $185.7m with 4.21m common shares at $46.5/share 2018-09-19
GeNeuro–Servier: investment, 201809 existent investor Servier 2018-09-18
Luciole Medical–SEVERAL: investment, 201809 financing round Series A CHF5.3m (€4.7m) led by SVC Ltd (CreditSuisse) 2018-09-17
Menarini–Lunaphore: staining technology, 201809– collab Menarini Diagnostics to market LabSat Frozen tissue staining solution 2018-09-09
Polyphor–Novo Group: investment, 201809 capital increase CHF6.8m with 179k shares at CHF38/share sold to Novo REPAIR Impact Fund 2018-09-06
Polyphor–Novo Group: investment, 201809– project-based + royalty-bearing investment up to CHF4.7m based on milestones in OMPTA program by Novo REPAIR 2018-09-06
Lunaphore–SEVERAL: investment, 201808 financing round Series B CHF5.3m from existing + new investors 2018-08-30
Novaremed–SEVERAL: investment, 201804 financing round CHF4.44m to support phase 2b study of NRD.E1 in DNP 2018-08-23
Novaremed–SEVERAL: investment, 201808 financing round CHF6m to support phase 2b study of NRD.E1 in DNP 2018-08-23
NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan 2018-08-16
Artios Pharma–Novartis: investment, 201808 financing round Series B totalling $84m incl new + co-investor Novartis Venture Fund 2018-08-10
Akouos–Novartis: investment, 201808 financing round Series A totalling $50m incl new co-investor Novartis Venture Fund 2018-08-07
B&W Tek–Metrohm: investment, 201807 acquisition €na of B&W Tek LLC + several overseas subisidiaries 2018-07-27
Novartis–MorphoSys: therapeutic antibody, 201807– license excl ww to MOR106 from MOR+GLPG €95m upfront + €850m milestones + royalties + funding 2018-07-19
Polares Medical–Decheng Capital: investment, 201807 financing round totalling $25m incl lead investor Decheng Capital 2018-07-17
Polares Medical–Earlybird: investment, 201807 financing round totalling $25m incl co-investor Earlybird Venture Capital Berlin 2018-07-17
Polares Medical–Endeavour Vision: investment, 201807 financing round totalling $25m incl co-investor Endeavour Vision 2018-07-17
Polares Medical–IDO Investments: investment, 201807 financing round totalling $25m incl co-investor IDO Investments 2018-07-17
Polares Medical–SEVERAL: investment, 201807 financing round $25m led by Decheng Capital 2018-07-17
Polares Medical–Wellington Partners: investment, 201807 financing round totalling $25m incl co-investor Wellington Partners 2018-07-17
Roche–Shionogi: virostatic agent, 201807 license to baloxavir marboxil excl ww without JP + TW to Roche existent 2018-07-17
Basilea–Coulter Partners: recruitment services, 201807 supply service placement of Gerrit Hauck as new CTO of Basilea Pharmaceutica Intl Ltd 2018-07-04
Novartis–France (govt): cell therapy contract manufacturing, 201807– supply production CAR-T cell therapies incl Kymriah by CellforCure 2018-07-01
NBE Therapeutics–Novo Group: investment, 201806 financing round Series B CHF20m extension by Novo Holdings bringing total Series B to CHF40m 2018-06-28
Bruker Corp–Cytosurge: cell analysis technology, 201806 collab product integration FluidFM techn on BioScope Resolve AMF for single cell analysis 2018-06-27
Nouscom–Minapharm: cell line, 201806– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines 2018-06-26
iTeos Therapeutics–HBM: investment, 201806 financing round Series B totalling €64m incl new + co-investor HBM Partners 2018-06-20
TG Therapeutics–Novimmune: bispecific antibody, 201806– collab + excl license option ww for CD47/CD19 antibody NI-1701 (TG-1801) 2018-06-20
Foundation Medicine–Roche: investment, 201806–201807 acquisition all remaining shares for $2.4b in cash at $137/share 2018-06-19
Interactive Biosoftware–Sophia Genetics: investment, 201806 acquisition of IBS by Sophia Genetics 2018-06-16
Andrew Alliance–Omega Advisors: investment, 201806 financing round Series C totalling $14m incl Omega Funds 2018-06-12
Andrew Alliance–SEVERAL: investment, 201806 financing round Series C $14m incl Tecan + Waters + Inpeco + Rancilio Cube + Sam Eletr + Omega Funds 2018-06-12
Andrew Alliance–Tecan: investment, 201806 financing round Series C totalling $14m incl Tecan Group 2018-06-12
Andrew Alliance–Waters: investment, 201806 financing round Series C totalling $14m incl Waters Corp 2018-06-12
Lunaphore–Vitro (ES): in situ hybridisation, 201805– collab developm ISH protocols for RNA + DNA targets in tissue 2018-05-24
Pierre Fabre–Roche: companion diagnostics, 201805– collab extension for developm of IHC CDx assay for ADC W0101 2018-05-18
Polyneuron–SEVERAL: investment, 201805 seed financing round CHF3.1m led by EVA Basel + incl Zürcher Kantonalbank + private investors 2018-05-14
Valerius Biopharma–Catalent: contract manufacturing, 201805– collab cell line developm + manufacturing of speciality biosimilars using GPEx technology 2018-05-14
Memo Therapeutics–Redalpine: investment, 201805 financing round Series A2 totalling CHF5m incl existing investor Redalpine Venture Partners 2018-05-09
Memo Therapeutics–Schroders: investment, 201805 financing round Series A2 totalling CHF5m incl new investor Schroder Adveq 2018-05-09
Memo Therapeutics–SEVERAL: investment, 201805 financing round Series A2 CHF5m incl Schroder Adveq + investiere.ch + Redalpine Ventures et al. 2018-05-09
Memo Therapeutics–Verve Capital Partners: investment, 201805 financing round Series A2 totalling CHF5m incl new investor investiere.ch 2018-05-09
Memo Therapeutics–Zürcher Kantonalbank: investment, 201805 financing round Series A2 totalling CHF5m incl existing investor ZKB 2018-05-09
Genohm–Agilent: investment, 201805 acquisition €na of Genohm by Agilent 2018-05-02
Roche–4D Molecular Therapeutics: gene delivery technology, 201804– collab expansion to develop + commercialise ophthalmic gene therapy products 2018-04-30
Polyphor–Consilium: public relations, 201804 service existent international media relations by CSC 2018-04-27
DKSH–Bruker Corp: analytical instruments, 201804– distribution multi-product line of Bruker AXS in KR + AU + NZ + SG + ID by DKSH Technology 2018-04-17
Enterprise Therapeutics–Novartis: investment, 201804 financing round Series B totalling £29m ($41m) incl co-lead investor Novartis Venture Fund 2018-04-12
Baliopharm–Promethera: investment, 201804 acquisition €na of Baliopharm AG by Promethera Biosciences SA 2018-04-10
AveXis–Novartis: investment, 201804–201805 acquisition $8.7b in cash of AveXis Inc by Novartis for $128/share 2018-04-09
Polyphor–SEVERAL: investment, 201804–201805 IPO CHF155m (€130m) at SIX Swiss Exchange at CHF38/share 2018-04-09
Macrolide–Novartis: investment, 201804 financing round totalling $20m incl existing investor Novartis Venture Fund 2018-04-01
Macrolide–Roche: investment, 201804 financing round totalling $20m incl existing investor Roche Ventures 2018-04-01
Novartis–GSK: investment, 201803– acquisition $13b of 36.5% stake of Novartis in OTC joint venture giving GSK 100% ownership 2018-03-27
NMD Pharma–Roche: investment, 201803 financing round Series A totalling €38m incl new + co-investor Roche Venture Fund 2018-03-23
Novartis–Harvard Univ: drug delivery technology, 201803– collab develop biomaterial systems for delivery of cancer immuntherapies NIBR + Wyss + Dana 2018-03-20
Compugen–JSR Corp: cell line development, 201803– license to use Selexis’ SUREtechnology for developm of cancer antibody drugs incl COM701 2018-03-07
1 2 3 4 5 6 7 8 9 10 11  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

» top